BRIEF published on 06/28/2024 at 07:05, 2 years ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
PRESS RELEASE published on 06/28/2024 at 07:00, 2 years ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
BRIEF published on 06/14/2024 at 18:35, 2 years 1 month ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 2 years 1 month ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
BRIEF published on 05/29/2024 at 19:32, 2 years 1 month ago GeNeuro: Information on the General Meeting of June 12, 2024 Shareholders Biopharmaceutical Multiple Sclerosis General Assembly GeNeuro
PRESS RELEASE published on 05/29/2024 at 19:27, 2 years 1 month ago Inside Information / Other news releases GeNeuro announces availability of documents for the annual shareholders’ meeting on June 12, 2024 in Geneva, Switzerland. Documents accessible online and at company headquarters Shareholders' Meeting Annual Meeting GeNeuro Geneva Documents Availability
BRIEF published on 04/30/2024 at 19:59, 2 years 2 months ago GeNeuro presents its 2023 annual results and progresses in its research programs Financial Results Long Covid Medical Research Health GeNeuro SA
PRESS RELEASE published on 04/30/2024 at 19:54, 2 years 2 months ago Inside Information / News release on accounts, results GeNeuro reports 2023 full-year results and provides corporate update including completion of Phase 2 trial for temelimab against post-COVID neuropsychiatric syndromes. Financial visibility extended to Q3 2024 Full-year Results Phase 2 Trial GeNeuro Temelimab Post-COVID
Published on 07/21/2026 at 01:00, 6 hours 59 minutes ago Namibia Critical Metals Launches Next Phase of Lofdal Definitive Feasibility Study Including Further Value Addition in Namibia
Published on 07/20/2026 at 22:30, 9 hours 29 minutes ago Fermi Announces Second Quarter 2026 Earnings Release and Call Date
Published on 07/20/2026 at 22:30, 9 hours 29 minutes ago Grid Metals Enters Into Joint Venture Agreement with Avenir Minerals for Falcon West Cesium Project
Published on 07/20/2026 at 22:15, 9 hours 44 minutes ago Gamma Announces $2.1 Million LIFE Private Placement Offering
Published on 07/20/2026 at 20:25, 11 hours 34 minutes ago Taranis Offers a Fully Domestic Source of Critical Minerals as it Initiates New Tests for Even More Critical Mineral Elements, and Acquires New Mineral Tenures at Thor Project
Published on 07/21/2026 at 07:35, 24 minutes ago REINET INVESTMENTS S.C.A. SHARE BUYBACK PROGRAMME – UPDATE 21 JULY 2026
Published on 07/21/2026 at 07:30, 29 minutes ago NET ASSET VALUE OF REINET FUND S.C.A., F.I.S. AS AT 30 JUNE 2026
Published on 07/21/2026 at 07:00, 59 minutes ago Presentation of the 2026 half-year results for the Julius Baer Group
Published on 07/21/2026 at 07:00, 59 minutes ago Lindt & Sprüngli reports solid half-year results and confirms full-year guidance
Published on 07/20/2026 at 18:20, 13 hours 39 minutes ago Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 13 hours 55 minutes ago Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:40, 14 hours 19 minutes ago Mersen selected to supply Ford and Leapmotor with fuses for electric vehicles
Published on 07/20/2026 at 14:25, 17 hours 34 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from July 13 to July 17 2026
